File Archive - Downers Documents - Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers (2007)

News Groups Blog Forum Chat Video Audio Images Documents Wiki Home

		Drugs Forum > File Archive > Documents > CHEMICAL & (SEMI-) SYNTHETIC DRUGS > Downers Documents
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers (2007)

Tags

FAQ n Rules

Mark Forums Read

Notices

Create a FREE account now to get access to more forums, more videos, more music, more documents, more images, more reviews, more news about drugs and much more functionality.
Start posting now, join our groups or create your unique profile.

links

Downers Documents

Documents about Benzodiazepines, Downers, Sleeping Pills, Z-drugs and Skeletal Muscle Relaxants

New entries announced in forum Downers and sleeping pills

Allowances: 4.88 Mbytes/1.52 Mbytes used

[RSS Feed]

Entries

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers (2007)

Left click: open entry/Right click: save entry

J Psychopharmacol. 2007 Jun;21(4):374-83

de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM.

TPA023, a GABA(A) alpha2,3 alphasubtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating effects. The compound lacks efficacy at the alpha1 subtype, which is believed to mediate these effects. This study investigated the effects of 0.5 and 1.5 mg TPA023 and compared them with placebo and lorazepam 2 mg (therapeutic anxiolytic dose). Twelve healthy male volunteers participated in this placebo-controlled, double-blind, double-dummy, four-way, cross-over study. Saccadic eye movements and visual analogue scales (VAS) were used to assess the sedative properties of TPA023. The effects on posturaL stability and cognition were assessed using body sway and a standardized battery of neurophysiological memory tests. Lorazepam caused a significant reduction in saccadic peak velocity, the VAS alertness score and impairment of memory and body sway. TPA023 had significant dose dependent effects on saccadic peak velocity (85 deg/sec maximum reduction at the higher dose) that approximated the effects of lorazepam. In contrast to lorazepam, TPA023 had no detectabLe effects on saccadic latency or inaccuracy. Also unlike lorazepam, TPA023 did not affect VAS alertness, memory or body sway. These results show that the effect profile of TPA023 differs markedly from that of lorazepam, at doses that were equipotent with regard to effects on saccadic peak veLocity. Contrary to lorazepam, TPA023 caused no detectable memory impairment or postural imbalance. These differences reflect the selectivity of TPA023 for different GABA(A) receptor subtypes.

Discussion Thread

Category Downers Documents

Submitted by Jatelka

27-01-2008
253.67 Kbytes Hits 15
Keywords: gaba lorazepam tpa023

Category

Forum Jump

Sitelinks:	Site Functions:
Homepage Wiki Documents Image Gallery Audio Video Forum Blog Groups News	Site Rules Frequently Asked Questions Register to Participate Did you forget your password? All Threads

All times are GMT +1. The time now is 20:06.